Dermata Therapeutics to Launch OTC Acne Kit by 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: NASDAQ.COM
Dermata Therapeutics Inc saw a price increase of 6.50% as it crossed above the 5-day SMA, reflecting positive market sentiment.
The company is set to introduce its first over-the-counter acne kit by mid-2026, utilizing its proprietary Spongilla technology, which has demonstrated clinical efficacy in treating moderate-to-severe acne. This strategic move aims to establish a strong brand identity in the OTC dermatology market.
With $4.7 million in cash as of September 30, 2025, Dermata is well-positioned to support its operations through the second quarter of 2026, potentially enhancing its market presence and driving future growth.
Analyst Views on DRMA
Wall Street analysts forecast DRMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.520
Low
10.00
Averages
10.00
High
10.00
Current: 2.520
Low
10.00
Averages
10.00
High
10.00
About DRMA
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
